C4U Corporation is focused on advancing new genome editing technologies with the aim of various industrial applications. The company has recently entered into a collaborative research agreement with Hiroshima University, indicating a commitment to leveraging academic partnerships for innovation. C4U is also actively participating in industry events, such as the BIO JAPAN and Japan Healthcare Venture Summit 2024, where they will showcase their developments and engage with potential partners. Their involvement in discussions about regenerative medicine highlights their role in shaping the future of healthcare in Japan.

In addition to their research initiatives, C4U has achieved significant milestones, including the issuance of a patent in India for a method to produce edited eukaryotic cells, which underscores their innovative capabilities in the field of genetic engineering. The company has also established collaborative agreements with other organizations, such as Site-Fact, to further enhance their research and development efforts. C4U's strategic focus on genome editing positions them as a key player in the biotechnology sector, with the potential to impact various industries through their cutting-edge technologies.

Japan

C4U is a biotechnology venture company from Osaka University, engaging in research and development of novel genome editing technology, CRISPR-Cas3. Utilizing newly invented cutting-edge genome editing technology, C4U promotes the development of new treatments for various diseases, including genetic diseases. C4U also collaborates with other companies and is working to develop platforms for applications in other industries.

吹田市山田丘2－8, TechnoAliance C-7F, Suita-shi, Yamadaoka 2-8 , Osaka 5650871, JP

C4U Corporation

Company Details